Status:
COMPLETED
Efficacy and Tolerability of an Intra-Nasal Testosterone Product
Lead Sponsor:
Acerus Pharmaceuticals Corporation
Conditions:
Hypogonadism
Eligibility:
MALE
18-80 years
Phase:
PHASE2
Brief Summary
This clinical trial is being performed to compare the pharmacokinetic profile of testosterone after repeated intra-nasal administration of products of different strengths in subjects with hypogonadism...
Detailed Description
Primary Objective: The primary objective of this study was to determine the efficacy of Nasobol in the treatment of hypogonadal men requiring testosterone replacement therapy. Efficacy was determined...
Eligibility Criteria
Inclusion
- Men with primary or secondary hypogonadism and a serum morning (0900 h ± 30 minutes) testosterone levels \>100 ng/dl and ≤ 300 ng/dL.
- Normal Otolaryngological nasal endoscopy examination.
- Normal prostate examination (no palpable prostatic mass), and serum PSA ≤ 4.0 ng/mL.
Exclusion
- Current treatment with other androgens (i.e. DHEA), anabolic steroids or other sex hormones
- Treatment with Estrogens, GnRH antagonists, or Growth Hormone within previous 12 months
- History of nasal surgery, specifically turbinoplasty, septoplasty, rhinoplasty, or sinus surgery.
- History of nasal disorders (e.g. polyposis, recurrent epistaxis ( \> 1 nose bleed per month, abuse of nasal decongestants) or sleep apnea.
Key Trial Info
Start Date :
August 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2010
Estimated Enrollment :
57 Patients enrolled
Trial Details
Trial ID
NCT00975650
Start Date
August 1 2009
End Date
May 1 2010
Last Update
August 13 2018
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Quality of Life Medical & Research centre
Tucson, Arizona, United States, 85712
2
Providence Clinical Research
Burbank, California, United States, 91505
3
Cetero Research
Miami Gardens, Florida, United States, 33169
4
Clinical Research Institute
Wichita, Kansas, United States, 67221